Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11204657 | 0.96 | CHRM2 (0.45) | CA12CA1CA2CA9CHRM2 | |
| SCHEMBL7718808 | 0.83 | CA12 (0.44) | CA12CA1CA2CA9CHRM2 | |
| SCHEMBL8893027 | 0.83 | CA12 (0.47) | CA12CA1CA2CA9CHRM2 | |
| SCHEMBL22325195 | 0.82 | CES2 (0.36) | KDM4EALDH1A1BLMPMP22HSD17B10 | |
| SCHEMBL6712841 | 0.82 | CES2 (0.36) | KDM4EALDH1A1BLMPMP22HSD17B10 | |
| SCHEMBL30661132 | 0.82 | CES2 (0.36) | KDM4EALDH1A1BLMPMP22HSD17B10 | |
| SCHEMBL6668639 | 0.82 | CES2 (0.36) | KDM4EALDH1A1BLMPMP22HSD17B10 | |
| SCHEMBL24784667 | 0.81 | BLM (0.48) | CA12CA1CA2CA9CHRM2 | |
| SCHEMBL280516 | 0.81 | CA12 (0.46) | CA12CA1CA2CA9CHRM2 | |
| SCHEMBL29638790 | 0.81 | BLM (0.48) | CA12CA1CA2CA9CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203030-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS, INC. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203030-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, MDM2, XIAP | CA12 3306/4885CA1 2530/4885CA2 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.